"Through our robust clinical trial program, we've been able to address important unanswered questions about optimal treatment with TAVR," said Rhonda Robb, vice president and general manager of Heart Valve Therapies at Medtronic. "The favorable outcomes from this analysis add to the growing body of clinical evidence that reinforce the positive performance of the CoreValve System, which to date is the only TAVR device to demonstrate significant clinical advantages in this important subgroup of high risk patients with prior-CABG procedures."

The CoreValve System is available for use in the United States, following U.S. Food and Drug Administration (FDA) approval in 2014 for patients at extreme risk and high risk for surgery. Since receiving CE (Conformité Européenne) Mark in 2007, the CoreValve System has been implanted in more than 70,000 patients in more than 60 countries. In addition, the CoreValve System offers the broadest range of sizes available to accommodate more patients.


In collaboration with leading clinicians, researchers and scientists worldwide, Medtronic offers the broadest range of innovative medical technology for the interventional and surgical treatment of cardiovascular disease and cardiac arrhythmias. The company strives to offer products and services that deliver clinical and economic value to healthcare consumers and providers around the world.

ABOUT MEDTRONIC
Medtronic plc (www.medtronic.com), headquartered in Dublin, is the global leader in medical technology - alleviating pain, restoring health and extending life for millions of people around the world.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

Contacts:
Joey Lomicky
Public Relations
+1-763-526-2494

Jeff Warren
Investor Relations
+1-763-505-2696

Back to HCB News

More HCB News